Durable, safe and effective long-term kidney drug data from Tricida fuel blockbuster potential
Kidney drug developer Tricida’s shares shot up on Thursday, after long-term data highlighted its lead drug’s durable efficacy and safety profile as a treatment for metabolic acidosis, in which faulty kidneys are not able to expel the acid causing a buildup in the body.
The drug — TRC101 — is designed to bind to hydrochloric acid in the GI tract, triggering the ejection of acid via excretion — thereby diminishing acid levels and stimulating blood bicarbonate. The company expects to submit an application to market the drug by the second half of this year for the condition commonly caused by chronic kidney disease (and believed to accelerate the progression of CKD), increase the risk of muscle wasting and cause the loss of bone density. If approved, it will be the first drug to win the FDA nod specifically for metabolic acidosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.